Every prospective delegate eventually asks the uncomfortable question. Is it too late, and is the market already full? It deserves a straight answer rather than a reassuring one.
The number behind the worry
A UCL study in February 2026 mapped 19,701 practitioners across 5,589 clinics, up from an estimated 3,600 in 2023, a 437 percent rise (Zargaran et al., Aesthetic Surgery Journal Open Forum). That is a lot of new entrants in a short time. Pretending otherwise would be insulting. In the low-differentiation end of the market, toxin and filler sold on price alone, it is genuinely crowded.
Where crowded stops being true
Saturation is uneven. The bottom of the market is packed. The part that can evidence medical training, handle complications, prescribe, and offer the regenerative and restoration work that is actually growing is not. As the licensing scheme pushes higher-risk procedures towards regulated professionals, a chunk of that 19,701 will face rising insurance and compliance costs they did not plan for. Some will leave. The barrier to entry is about to go up, which is bad news for the crowd and good news for anyone entering properly.
The honest read
If you want to compete on being the cheapest injector in a commuter town, yes, you are late. If you want to be the clinically credible practitioner who does the work the crowd cannot, the timing is fine, arguably good, because the regulation clearing the field arrives just as you qualify. Our state of the sector page has the wider picture, and the route finder helps you find the gap that fits your background.
The takeaway
Oversaturated is the wrong word. Unevenly saturated is the right one, and the empty part of the map is the part that rewards a medical background.